216 related articles for article (PubMed ID: 12028831)
1. Tumor cell depletion of peripheral blood progenitor cells using positive and positive/negative selection in metastatic breast cancer.
Preti RA; Lazarus HM; Winter J; Stadtmauer EA; Nadasi S; McMannis J; Karandish S; Jennis A; Goldberg SL; Pecora AL
Cytotherapy; 2001; 3(2):85-95. PubMed ID: 12028831
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE
Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736
[TBL] [Abstract][Full Text] [Related]
3. Combined positive/negative purging and transplantation of peripheral blood progenitor cell autografts in breast cancer patients: a pilot study.
Mapara MY; Körner IJ; Lentzsch S; Krahl D; Reichardt P; Dörken B
Exp Hematol; 1999 Jan; 27(1):169-75. PubMed ID: 9923456
[TBL] [Abstract][Full Text] [Related]
4. Transplantation of CD34+ peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: results of a prospective randomized multicenter clinical trial.
Yanovich S; Mitsky P; Cornetta K; Maziarz RT; Rosenfeld C; Krause DS; Lotz JP; Bitran JD; Williams S; Preti R; Somlo G; Burtness B; Mills B
Bone Marrow Transplant; 2000 Jun; 25(11):1165-74. PubMed ID: 10849529
[TBL] [Abstract][Full Text] [Related]
5. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction.
Mapara MY; Körner IJ; Hildebrandt M; Bargou R; Krahl D; Reichardt P; Dörken B
Blood; 1997 Jan; 89(1):337-44. PubMed ID: 8978310
[TBL] [Abstract][Full Text] [Related]
6. Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer.
Schwella N; Beyer J; Schwaner I; Heuft HG; Rick O; Huhn D; Serke S; Siegert W
J Clin Oncol; 1996 Apr; 14(4):1114-21. PubMed ID: 8648365
[TBL] [Abstract][Full Text] [Related]
7. Peripheral blood CD34+ cell immunomagnetic selection in breast cancer patients: effect on hematopoietic progenitor content and hematologic recovery after high-dose chemotherapy and autotransplantation.
Cancelas JA; Querol S; Canals C; Picón M; Azqueta C; Solà C; Montes A; Amill B; Griera E; Inglés J; López JJ; Germà JR; García-López J
Transfusion; 1998; 38(11-12):1063-70. PubMed ID: 9838939
[TBL] [Abstract][Full Text] [Related]
8. CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.
Papadopoulos KP; Ayello J; Reiss RF; Troxel A; Kaufman E; Vahdat LT; Antman KH; Hesdorffer CS
J Hematother Stem Cell Res; 1999 Aug; 8(4):357-63. PubMed ID: 10634173
[TBL] [Abstract][Full Text] [Related]
9. Isolation and transplantation of highly purified autologous peripheral CD34+progenitor cells: purging efficacy, hematopoietic reconstitution following high dose chemotherapy in patients with breast cancer: results of a feasibility study in Japan.
Chou T; Sano M; Ogura M; Morishima Y; Itagaki H; Tokuda Y
Breast Cancer; 2005; 12(3):178-88. PubMed ID: 16110287
[TBL] [Abstract][Full Text] [Related]
10. Autologous peripheral blood progenitor cell transplantation with <2 x 10(6) CD34(+)/kg: an analysis of variables concerning mobilisation and engraftment.
Villalón L; Odriozola J; Laraña JG; Zamora C; Pérez de Oteyza J; Jodra MH; López J; Herrera P; Roldán E; Ramos ML; Ramos P; Navarro JL
Hematol J; 2000; 1(6):374-81. PubMed ID: 11920217
[TBL] [Abstract][Full Text] [Related]
11. Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin.
Brugger W; Henschler R; Heimfeld S; Berenson RJ; Mertelsmann R; Kanz L
Blood; 1994 Sep; 84(5):1421-6. PubMed ID: 7520769
[TBL] [Abstract][Full Text] [Related]
12. Negative immunomagnetic purging of peripheral blood stem cell harvests from breast carcinoma patients reduces tumor cell contamination while not affecting hematopoietic recovery.
Pedrazzoli P; Lanza A; Battaglia M; Da Prada GA; Zambelli A; Perotti C; Ponchio L; Salvaneschi L; Robustelli della Cuna G
Cancer; 2000 Jun; 88(12):2758-65. PubMed ID: 10870058
[TBL] [Abstract][Full Text] [Related]
13. Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer.
Negrin RS; Atkinson K; Leemhuis T; Hanania E; Juttner C; Tierney K; Hu WW; Johnston LJ; Shizurn JA; Stockerl-Goldstein KE; Blume KG; Weissman IL; Bower S; Baynes R; Dansey R; Karanes C; Peters W; Klein J
Biol Blood Marrow Transplant; 2000; 6(3):262-71. PubMed ID: 10871151
[TBL] [Abstract][Full Text] [Related]
14. Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma.
Abonour R; Scott KM; Kunkel LA; Robertson MJ; Hromas R; Graves V; Lazaridis EN; Cripe L; Gharpure V; Traycoff CM; Mills B; Srour EF; Cornetta K
Bone Marrow Transplant; 1998 Nov; 22(10):957-63. PubMed ID: 9849692
[TBL] [Abstract][Full Text] [Related]
15. Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy.
Prince HM; Bashford J; Wall D; Rischin D; Parker N; Toner GC; Seymour JF; Blakey D; Haylock D; Simmons P; Francis P; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P
Cytotherapy; 2002; 4(2):137-45. PubMed ID: 12006209
[TBL] [Abstract][Full Text] [Related]
16. [Effect of immunomagnetic selection in purging autologous peripheral blood progenitor cell of breast cancer patients].
Han X; Shi Y; Zhang W
Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(3):203-6. PubMed ID: 11953162
[TBL] [Abstract][Full Text] [Related]
17. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
[TBL] [Abstract][Full Text] [Related]
18. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing collection and engraftment of CD34+ cells in patients with breast cancer following high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation.
Canales MA; Arrieta R; Hernández-García MC; Ojeda E; Díez J; Calero F; Aguado MJ; Bustos JG; Hernández-Navarro F
J Hematother Stem Cell Res; 2000 Feb; 9(1):103-9. PubMed ID: 10738978
[TBL] [Abstract][Full Text] [Related]
20. Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery.
Dreger P; Viehmann K; von Neuhoff N; Glaubitz T; Petzoldt O; Glass B; Uharek L; Rautenberg P; Suttorp M; Mills B; Mitsky P; Schmitz N
Bone Marrow Transplant; 1999 Jul; 24(2):153-61. PubMed ID: 10455343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
